Nondopaminergic mechanisms in levodopa‐induced dyskinesia
- 8 July 2005
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 20 (8) , 919-931
- https://doi.org/10.1002/mds.20612
Abstract
It has become increasingly apparent that Parkinson's disease involves many transmitter systems other than dopamine. This nondopaminergic involvement impacts on the generation of symptoms, on the neurodegenerative process, but, most tellingly, in the generation of side effects of current treatments, in particular, levodopa‐induced dyskinesia (LID). Such mechanisms contribute not only to the expression of LID once it has been established but also to the mechanisms responsible for the development, or priming, of the dyskinetic state and the subsequent maintenance of the brain in that primed state. Within the basal ganglia, abnormalities in different nondopaminergic components of the circuitry have been defined in LID. In particular, a role for enhanced inhibition of basal ganglia outputs by the GABAergic direct pathway has been suggested as a basic mechanism generating LID. We speculate that the external globus pallidus and subthalamic nucleus may play distinct roles in different forms of dyskinesia, e.g., chorea/dystonia; peak/diphasic/off. At the cellular level, an appreciation of abnormal signaling by, among others, glutamatergic (NMDA and AMPA receptors in particular), α2 adrenergic, serotonergic (5HT), cannabinoid and opioid mechanisms in both priming and expression of LID has begun to emerge over the last decade. This is being consolidated, though in many cases questions remain regarding the specific sites of such abnormality within the circuitry. Very recently, at the molecular level, mechanisms controlling neurotransmitter release and impacting on the ability of neurons to maintain particular forms of firing patterning and synchronization, e.g., SV2A, have been identified. This increased understanding has already delivered and will continue to define novel approaches to treatment that target both pre‐ and postsynaptic signaling molecules throughout the basal ganglia circuitry. © 2005 Movement Disorder SocietyKeywords
This publication has 129 references indexed in Scilit:
- Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's diseaseMovement Disorders, 2003
- NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signalingNature Neuroscience, 2002
- Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high‐dose levodopa in the reserpine‐treated rat model of Parkinson's diseaseMovement Disorders, 2002
- Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonismJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2002
- Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's diseaseMovement Disorders, 2002
- Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosetsEuropean Journal of Neuroscience, 2001
- The ?2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions ofL-dopa in the MPTP-lesioned primate model of Parkinson's diseaseMovement Disorders, 1999
- Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's diseaseMovement Disorders, 1994
- Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: Relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptakeNeuroscience Letters, 1986
- GABA as the pallidothalamic neurotransmitter: implications for basal ganglia functionBrain Research, 1981